Complications of induced hypertension for delayed cerebral ischaemia secondary to aneurysmal subarachnoid haemorrhage.

IF 1.1 4区 医学 Q3 ANESTHESIOLOGY
Timothy P Webber, Benjamin J Young, Marianne J Chapman, Mark E Finnis
{"title":"Complications of induced hypertension for delayed cerebral ischaemia secondary to aneurysmal subarachnoid haemorrhage.","authors":"Timothy P Webber, Benjamin J Young, Marianne J Chapman, Mark E Finnis","doi":"10.1177/0310057X251330315","DOIUrl":null,"url":null,"abstract":"<p><p>The study objective was to determine the incidence of complications from induced hypertension used to treat delayed cerebral ischaemia (DCI) complicating aneurysmal subarachnoid haemorrhage (aSAH). Induced hypertension (IH) was defined as the use of vasopressors to achieve a supraphysiological systolic blood pressure target. A single-centre retrospective, observational cohort study was undertaken at the Royal Adelaide Hospital intensive care unit. Data are presented as predominantly median (interquartile range (IQR)). All patients admitted with a diagnosis of aSAH between 1 April 2020 and 1 April 2022 were included and analysed according to whether they did or did not receive vasopressors for IH. A total of 109 patients were included, of which 29 (27%) received vasopressors for IH (median age 58 (IQR 52-65) years, 65% female) and 80 did not receive IH (median age 55 (IQR 49-71) years, 62% female). Clinical DCI or radiological evidence of vasospasm were present in all patients given IH and in 16% of non-IH patients. Patients in the IH group had more ischaemic electrocardiogram (ECG) changes (17.2% <i>vs</i> 2.5%, <i>P</i> = 0.01), urine output (4807 (IQR 3186-5720) ml/day <i>vs</i> 2125 (IQR 1650-2760) ml/day, <i>P</i> < 0.001), fluid administration (4895 (IQR 3555-5999) ml/day <i>vs</i> 2704 (IQR 2300-3403) ml/day, <i>P</i> < 0.001) and intravenous potassium replacement (13 (IQR 5-24) mmol/day <i>vs</i> 5 (IQR 0-13) mmol/day, <i>P</i> = 0.001) than those in the non-IH group. IH was also associated with a greater incidence of hyponatraemia (58% <i>vs</i> 34%, <i>P</i> = 0.02). IH was not associated with arrhythmias or rebleeding. Mortality rates were 17% <i>vs</i> 20% (<i>P</i> > 0.9) in the IH and non-IH groups respectively. In conclusion, IH for the treatment of DCI following aSAH was associated with an increased rate of ischaemic ECG changes, increased urine output and hyponatraemia. However, in the IH group there was no increased rate of rebleeding, and 48% of the IH patients had an improvement in their neurological function following commencement of treatment.</p>","PeriodicalId":7746,"journal":{"name":"Anaesthesia and Intensive Care","volume":" ","pages":"310057X251330315"},"PeriodicalIF":1.1000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anaesthesia and Intensive Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/0310057X251330315","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The study objective was to determine the incidence of complications from induced hypertension used to treat delayed cerebral ischaemia (DCI) complicating aneurysmal subarachnoid haemorrhage (aSAH). Induced hypertension (IH) was defined as the use of vasopressors to achieve a supraphysiological systolic blood pressure target. A single-centre retrospective, observational cohort study was undertaken at the Royal Adelaide Hospital intensive care unit. Data are presented as predominantly median (interquartile range (IQR)). All patients admitted with a diagnosis of aSAH between 1 April 2020 and 1 April 2022 were included and analysed according to whether they did or did not receive vasopressors for IH. A total of 109 patients were included, of which 29 (27%) received vasopressors for IH (median age 58 (IQR 52-65) years, 65% female) and 80 did not receive IH (median age 55 (IQR 49-71) years, 62% female). Clinical DCI or radiological evidence of vasospasm were present in all patients given IH and in 16% of non-IH patients. Patients in the IH group had more ischaemic electrocardiogram (ECG) changes (17.2% vs 2.5%, P = 0.01), urine output (4807 (IQR 3186-5720) ml/day vs 2125 (IQR 1650-2760) ml/day, P < 0.001), fluid administration (4895 (IQR 3555-5999) ml/day vs 2704 (IQR 2300-3403) ml/day, P < 0.001) and intravenous potassium replacement (13 (IQR 5-24) mmol/day vs 5 (IQR 0-13) mmol/day, P = 0.001) than those in the non-IH group. IH was also associated with a greater incidence of hyponatraemia (58% vs 34%, P = 0.02). IH was not associated with arrhythmias or rebleeding. Mortality rates were 17% vs 20% (P > 0.9) in the IH and non-IH groups respectively. In conclusion, IH for the treatment of DCI following aSAH was associated with an increased rate of ischaemic ECG changes, increased urine output and hyponatraemia. However, in the IH group there was no increased rate of rebleeding, and 48% of the IH patients had an improvement in their neurological function following commencement of treatment.

动脉瘤性蛛网膜下腔出血继发迟发性脑缺血诱发高血压的并发症。
研究目的是确定用于治疗迟发性脑缺血(DCI)并发动脉瘤性蛛网膜下腔出血(aSAH)的诱发高血压的并发症发生率。诱导性高血压(IH)被定义为使用血管加压药物来达到生理上的收缩压目标。在皇家阿德莱德医院重症监护室进行了一项单中心回顾性观察队列研究。数据主要以中位数(四分位间距(IQR))表示。所有在2020年4月1日至2022年4月1日期间被诊断为aSAH的患者被纳入研究,并根据他们是否接受血管加压药物治疗IH进行分析。共纳入109例患者,其中29例(27%)接受血管加压药治疗IH(中位年龄58 (IQR 52-65)岁,65%为女性),80例未接受血管加压药治疗(中位年龄55 (IQR 49-71)岁,62%为女性)。所有接受IH治疗的患者和16%的非IH患者均存在血管痉挛的临床DCI或影像学证据。IH组患者的缺血性心电图(ECG)变化(17.2% vs 2.5%, P = 0.01),尿量(4807 (IQR 3186-5720) ml/天vs 2125 (IQR 1650-2760) ml/天,P vs 2704 (IQR 2300-3403) ml/天,P vs 5 (IQR 0-13) mmol/天,P = 0.001)高于非IH组。IH还与较高的低钠血症发生率相关(58% vs 34%, P = 0.02)。IH与心律失常或再出血无关。IH组和非IH组的死亡率分别为17%和20% (P < 0.05)。总之,治疗aSAH后DCI的IH与缺血性心电图变化率增加、尿量增加和低钠血症相关。然而,在IH组中,再出血率没有增加,并且48%的IH患者在开始治疗后神经功能有所改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.70
自引率
13.30%
发文量
150
审稿时长
3 months
期刊介绍: Anaesthesia and Intensive Care is an international journal publishing timely, peer reviewed articles that have educational value and scientific merit for clinicians and researchers associated with anaesthesia, intensive care medicine, and pain medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信